The FDA has granted wound care startup Gel-e breakthrough status designation for its Life Foam expanding, injectable hemostat. The internal-use flowable device is intended for rapidly providing temporary bleeding control in patients with non-compressible abdominal wounds not suited for tourniquet use in battlefield and trauma conditions.
Gel-e's internal bleeding control device nabs breakthrough status
Sign up for FDLI SmartBrief
News for the food and drug law community
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.